Krystal Biotech, Inc. (KRYS) 10-Year Financial Performance & Capital Metrics

KRYS • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutKrystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.Show more

Revenue $291M +473.0%
EBITDA $72M +169.7%
Net Income $89M +715.6%
EPS (Diluted) 3.00 +669.2%
Gross Margin 93.09% -0.9%
EBITDA Margin 24.92% +112.2%
Operating Margin 22.61% +110.4%
Net Margin 30.69% +42.3%
ROE 10.34% +515.0%
ROIC 9.5% +146.0%
Debt/Equity 0.01 -26.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓FCF machine: 41.0% free cash flow margin
✓Momentum leader: RS Rating 91 (top 9%)
✓High quality earnings: Operating CF exceeds net income
✓Healthy 5Y average net margin of 26.1%
✓Trading near 52-week high

✗Weaknesses

✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM54.51%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM279.8%

EPS CAGR

10Y-

5Y-

3Y-

TTM276.85%

ROCE

10Y Avg-18.18%

5Y Avg-12.65%

3Y Avg-11.61%

Latest7.56%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	1.03M	0	0	0	0	50.7M	290.51M
Revenue Growth %	-	-	-	-1%	-	-	-	-	4.73%
Cost of Goods Sold+	2K	23K	141K	974K	1.85M	0	0	3.09M	20.06M
COGS % of Revenue	-	-	0.14%	-	-	-	-	0.06%	0.07%
Gross Profit+	-2K	-23K	886K	-974K	-1.85M	0	0	47.6M	270.45M
Gross Margin %	-	-	0.86%	-	-	-	-	0.94%	0.93%
Gross Profit Growth %	-	-10.5%	39.52%	-2.1%	-0.9%	1%	-	-	4.68%
Operating Expenses+	1.14M	4.77M	11.92M	22.08M	31.15M	68.28M	145.2M	157.33M	204.76M
OpEx % of Revenue	-	-	11.6%	-	-	-	-	3.1%	0.7%
Selling, General & Admin	402K	1.56M	4.16M	6.46M	13.21M	40.39M	77.73M	98.4M	113.69M
SG&A % of Revenue	-	-	4.05%	-	-	-	-	1.94%	0.39%
Research & Development	741K	3.21M	7.76M	15.62M	17.94M	27.88M	42.46M	46.43M	53.57M
R&D % of Revenue	-	-	7.56%	-	-	-	-	0.92%	0.18%
Other Operating Expenses	0	0	0	0	0	0	25M	12.5M	37.5M
Operating Income+	-1.14M	-4.77M	-11.92M	-22.08M	-33M	-68.28M	-145.2M	-109.73M	65.69M
Operating Margin %	-	-	-11.6%	-	-	-	-	-2.16%	0.23%
Operating Income Growth %	-	-3.17%	-1.5%	-0.85%	-0.49%	-1.07%	-1.13%	0.24%	1.6%
EBITDA+	-1.14M	-4.75M	-11.78M	-21.11M	-31.15M	-66.43M	-141.81M	-103.82M	72.41M
EBITDA Margin %	-	-	-11.47%	-	-	-	-	-2.05%	0.25%
EBITDA Growth %	-	-3.16%	-1.48%	-0.79%	-0.48%	-1.13%	-1.13%	0.27%	1.7%
D&A (Non-Cash Add-back)	2K	23K	141K	974K	1.85M	1.85M	3.38M	5.91M	6.71M
EBIT	-1.14M	-4.66M	-10.89M	-19.09M	-32.17M	-68.08M	-120.2M	-97.23M	103.19M
Net Interest Income+	0	0	0	2.99M	832K	-1.29M	5.22M	22.62M	29.66M
Interest Income	0	0	0	2.99M	832K	197K	5.22M	22.62M	29.66M
Interest Expense	7K	3.15M	1.03M	0	0	1.49M	0	0	0
Other Income/Expense	-7K	-3.15M	1.03M	2.99M	832K	-1.29M	5.22M	122.62M	29.66M
Pretax Income+	-1.15M	-7.92M	-10.89M	-19.09M	-32.17M	-69.57M	-139.97M	12.9M	95.36M
Pretax Margin %	-	-	-10.6%	-	-	-	-	0.25%	0.33%
Income Tax+	0	0	-20.14K	0	0	0	0	1.97M	6.2M
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	0.85%	0.94%
Net Income+	-1.15M	-7.92M	-10.89M	-19.09M	-32.17M	-69.57M	-139.97M	10.93M	89.16M
Net Margin %	-	-	-10.6%	-	-	-	-	0.22%	0.31%
Net Income Growth %	-	-5.89%	-0.37%	-0.75%	-0.69%	-1.16%	-1.01%	1.08%	7.16%
Net Income (Continuing)	-1.15M	-7.92M	-10.89M	-19.09M	-32.17M	-69.57M	-139.97M	10.93M	89.16M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.27	-1.48	-0.97	-1.20	-1.71	-3.13	-5.49	0.39	3.00
EPS Growth %	-	-4.48%	0.34%	-0.24%	-0.42%	-0.83%	-0.75%	1.07%	6.69%
EPS (Basic)	-0.27	-1.48	-0.97	-1.20	-1.71	-3.13	-5.49	0.40	3.12
Diluted Shares Outstanding	4.28M	5.36M	11.2M	15.9M	18.79M	22.2M	25.49M	27.75M	29.74M
Basic Shares Outstanding	4.28M	5.36M	11.2M	15.9M	18.79M	22.2M	25.49M	27.15M	28.59M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.17M	49.91M	112.65M	195.88M	275.06M	442.27M	383.78M	587.91M	742.04M
Cash & Short-Term Investments	1.92M	49.59M	111.76M	193.69M	271.26M	438.1M	379.17M	532.18M	597.52M
Cash Only	1.92M	49.59M	103.67M	187.51M	268.27M	341.25M	161.9M	358.33M	344.87M
Short-Term Investments	0	0	8.09M	6.17M	2.99M	96.85M	217.27M	173.85M	252.65M
Accounts Receivable	0	0	0	0	0	0	0	42.04M	104.75M
Days Sales Outstanding	-	-	-	-	-	-	-	302.66	131.6
Inventory	0	0	0	0	0	0	0	6.99M	26.51M
Days Inventory Outstanding	-	-	-	-	-	-	-	824.02	482.3
Other Current Assets	0	0	0	0	0	0	4.61M	6.71M	13.27M
Total Non-Current Assets+	13K	200K	3.47M	13.14M	35.79M	184.03M	174.67M	230.45M	313.79M
Property, Plant & Equipment	13K	200K	3.01M	11.18M	34.17M	119.58M	169.73M	168.23M	161.45M
Fixed Asset Turnover	-	-	0.34x	-	-	-	-	0.30x	1.80x
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	497K	0	64.37M	4.62M	61.95M	152.11M
Other Non-Current Assets	0	0	452K	1.46M	1.61M	74K	324K	263K	231K
Total Assets+	2.18M	50.11M	116.12M	209.02M	310.84M	626.29M	558.45M	818.36M	1.06B
Asset Turnover	-	-	0.01x	-	-	-	-	0.06x	0.28x
Asset Growth %	-	21.97%	1.32%	0.8%	0.49%	1.01%	-0.11%	0.47%	0.29%
Total Current Liabilities+	43K	640K	2.6M	3.33M	15.45M	25.74M	28.85M	33.09M	102M
Accounts Payable	42K	193K	888K	1.02M	2.1M	8.4M	3.98M	1.85M	4.99M
Days Payables Outstanding	7.67K	3.06K	2.3K	382.61	415.09	-	-	218.13	90.7
Short-Term Debt	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	437K	1.36M	12K	26K	87K	267K	16.75M	2.4M
Current Ratio	50.44x	77.99x	43.39x	58.88x	17.80x	17.18x	13.30x	17.76x	7.28x
Quick Ratio	50.44x	77.99x	43.39x	58.88x	17.80x	17.18x	13.30x	17.55x	7.02x
Cash Conversion Cycle	-	-	-	-	-	-	-	908.56	523.2
Total Non-Current Liabilities+	1.85M	0	294K	2.78M	3.31M	6.98M	7.37M	6.62M	7.46M
Long-Term Debt	1.84M	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	2.78M	3.31M	6.98M	7.37M	6.62M	6.04M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	7K	0	294K	0	0	0	0	0	1.42M
Total Liabilities	1.89M	640K	2.89M	6.11M	18.76M	32.72M	36.22M	39.71M	109.46M
Total Debt+	1.84M	0	0	3.26M	11.55M	8.02M	8.93M	8.09M	7.26M
Net Debt	-80K	-49.59M	-103.67M	-184.25M	-256.72M	-333.22M	-152.97M	-350.23M	-337.6M
Debt / Equity	6.38x	-	-	0.02x	0.04x	0.01x	0.02x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	0.10x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-4.66x
Interest Coverage	-163.29x	-1.52x	-11.60x	-	-	-45.76x	-	-	-
Total Equity+	289K	49.47M	113.23M	202.91M	292.08M	593.58M	522.23M	778.64M	946.38M
Equity Growth %	-	170.19%	1.29%	0.79%	0.44%	1.03%	-0.12%	0.49%	0.22%
Book Value per Share	0.07	9.23	10.11	12.76	15.55	26.74	20.49	28.06	31.82
Total Shareholders' Equity	289K	49.47M	113.23M	202.91M	292.08M	593.58M	522.23M	778.64M	946.38M
Common Stock	0	0	0	0	0	0	0	0	0
Retained Earnings	-1.15M	-9.07M	-19.96M	-39.05M	-71.21M	-140.78M	-280.76M	-269.83M	-180.67M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-2K	-25K	2K	10K	6K	-163K	-728K	638K	-190K
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.31M	-3.89M	-9.45M	-18.71M	-26.08M	-47.94M	-100.57M	-88.8M	123.42M
Operating CF Margin %	-	-	-9.2%	-	-	-	-	-1.75%	0.42%
Operating CF Growth %	-	-1.97%	-1.43%	-0.98%	-0.39%	-0.84%	-1.1%	0.12%	2.39%
Net Income	-1.15M	-7.92M	-10.89M	-19.09M	-32.17M	-69.57M	-139.97M	10.93M	89.16M
Depreciation & Amortization	2K	23K	141K	748K	1.85M	2.77M	4.05M	5.01M	6.71M
Stock-Based Compensation	33K	246K	792K	1.24M	3.27M	15.32M	33.23M	39.93M	49.13M
Deferred Taxes	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	7K	3.26M	962K	67K	33K	1.49M	-690K	-106.79M	-7.12M
Working Capital Changes	-203K	498K	511K	-1.68M	928K	2.05M	2.81M	-37.88M	-14.46M
Change in Receivables	0	0	0	0	0	0	0	-42.04M	-62.71M
Change in Inventory	0	0	0	0	0	0	0	-4.47M	-11.91M
Change in Payables	42K	133K	112K	-199K	783K	712K	-1.25M	-101K	1.01M
Cash from Investing+	-15K	-210K	-10.32M	-4.97M	-11.18M	-226.77M	-114.08M	82.64M	-163.44M
Capital Expenditures	-15K	-210K	-2.23M	-6.4M	-14.84M	-68.34M	-52.98M	-11.8M	-4.24M
CapEx % of Revenue	-	-	2.18%	-	-	-	-	0.23%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	100M	0
Cash from Financing+	3.25M	51.77M	73.85M	107.53M	118.02M	347.69M	35.35M	202.75M	27.01M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	-7.96M	-649K	-749K	-5.39M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.33M	-4.1M	-11.68M	-25.11M	-40.93M	-116.27M	-153.55M	-100.6M	119.18M
FCF Margin %	-	-	-11.37%	-	-	-	-	-1.98%	0.41%
FCF Growth %	-	-2.09%	-1.85%	-1.15%	-0.63%	-1.84%	-0.32%	0.34%	2.18%
FCF per Share	-0.31	-0.76	-1.04	-1.58	-2.18	-5.24	-6.02	-3.63	4.01
FCF Conversion (FCF/Net Income)	1.14x	0.49x	0.87x	0.98x	0.81x	0.69x	0.72x	-8.12x	1.38x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	5.67M

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-397.92%	-31.83%	-13.39%	-12.08%	-13%	-15.71%	-25.09%	1.68%	10.34%
Return on Invested Capital (ROIC)	-	-7780.43%	-189.36%	-117.38%	-91.62%	-34.63%	-34.59%	-20.63%	9.5%
Gross Margin	-	-	86.27%	-	-	-	-	93.9%	93.09%
Net Margin	-	-	-1060.27%	-	-	-	-	21.56%	30.69%
Debt / Equity	6.38x	-	-	0.02x	0.04x	0.01x	0.02x	0.01x	0.01x
Interest Coverage	-163.29x	-1.52x	-11.60x	-	-	-45.76x	-	-	-
FCF Conversion	1.14x	0.49x	0.87x	0.98x	0.81x	0.69x	0.72x	-8.12x	1.38x
Revenue Growth	-	-	-	-100%	-	-	-	-	473.02%

Frequently Asked Questions

Valuation & Price

Krystal Biotech, Inc. (KRYS) has a price-to-earnings (P/E) ratio of 94.0x. This suggests investors expect higher future growth.

Growth & Financials

Krystal Biotech, Inc. (KRYS) reported $373.2M in revenue for fiscal year 2024.

Krystal Biotech, Inc. (KRYS) grew revenue by 473.0% over the past year. This is strong growth.

Yes, Krystal Biotech, Inc. (KRYS) is profitable, generating $198.9M in net income for fiscal year 2024 (30.7% net margin).

Dividend & Returns

Krystal Biotech, Inc. (KRYS) has a return on equity (ROE) of 10.3%. This is reasonable for most industries.

Krystal Biotech, Inc. (KRYS) generated $165.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Krystal Biotech, Inc. (KRYS) 10-Year Financial Performance & Capital Metrics

KRYS • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $291M +473.0%
EBITDA $72M +169.7%
Net Income $89M +715.6%
EPS (Diluted) 3.00 +669.2%
Gross Margin 93.09% -0.9%
EBITDA Margin 24.92% +112.2%
Operating Margin 22.61% +110.4%
Net Margin 30.69% +42.3%
ROE 10.34% +515.0%
ROIC 9.5% +146.0%
Debt/Equity 0.01 -26.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓FCF machine: 41.0% free cash flow margin
✓Momentum leader: RS Rating 91 (top 9%)
✓High quality earnings: Operating CF exceeds net income
✓Healthy 5Y average net margin of 26.1%
✓Trading near 52-week high

✗Weaknesses

✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM54.51%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM279.8%

EPS CAGR

10Y-

5Y-

3Y-

TTM276.85%

ROCE

10Y Avg-18.18%

5Y Avg-12.65%

3Y Avg-11.61%

Latest7.56%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	1.03M	0	0	0	0	50.7M	290.51M
Revenue Growth %	-	-	-	-1%	-	-	-	-	4.73%
Cost of Goods Sold+	2K	23K	141K	974K	1.85M	0	0	3.09M	20.06M
COGS % of Revenue	-	-	0.14%	-	-	-	-	0.06%	0.07%
Gross Profit+	-2K	-23K	886K	-974K	-1.85M	0	0	47.6M	270.45M
Gross Margin %	-	-	0.86%	-	-	-	-	0.94%	0.93%
Gross Profit Growth %	-	-10.5%	39.52%	-2.1%	-0.9%	1%	-	-	4.68%
Operating Expenses+	1.14M	4.77M	11.92M	22.08M	31.15M	68.28M	145.2M	157.33M	204.76M
OpEx % of Revenue	-	-	11.6%	-	-	-	-	3.1%	0.7%
Selling, General & Admin	402K	1.56M	4.16M	6.46M	13.21M	40.39M	77.73M	98.4M	113.69M
SG&A % of Revenue	-	-	4.05%	-	-	-	-	1.94%	0.39%
Research & Development	741K	3.21M	7.76M	15.62M	17.94M	27.88M	42.46M	46.43M	53.57M
R&D % of Revenue	-	-	7.56%	-	-	-	-	0.92%	0.18%
Other Operating Expenses	0	0	0	0	0	0	25M	12.5M	37.5M
Operating Income+	-1.14M	-4.77M	-11.92M	-22.08M	-33M	-68.28M	-145.2M	-109.73M	65.69M
Operating Margin %	-	-	-11.6%	-	-	-	-	-2.16%	0.23%
Operating Income Growth %	-	-3.17%	-1.5%	-0.85%	-0.49%	-1.07%	-1.13%	0.24%	1.6%
EBITDA+	-1.14M	-4.75M	-11.78M	-21.11M	-31.15M	-66.43M	-141.81M	-103.82M	72.41M
EBITDA Margin %	-	-	-11.47%	-	-	-	-	-2.05%	0.25%
EBITDA Growth %	-	-3.16%	-1.48%	-0.79%	-0.48%	-1.13%	-1.13%	0.27%	1.7%
D&A (Non-Cash Add-back)	2K	23K	141K	974K	1.85M	1.85M	3.38M	5.91M	6.71M
EBIT	-1.14M	-4.66M	-10.89M	-19.09M	-32.17M	-68.08M	-120.2M	-97.23M	103.19M
Net Interest Income+	0	0	0	2.99M	832K	-1.29M	5.22M	22.62M	29.66M
Interest Income	0	0	0	2.99M	832K	197K	5.22M	22.62M	29.66M
Interest Expense	7K	3.15M	1.03M	0	0	1.49M	0	0	0
Other Income/Expense	-7K	-3.15M	1.03M	2.99M	832K	-1.29M	5.22M	122.62M	29.66M
Pretax Income+	-1.15M	-7.92M	-10.89M	-19.09M	-32.17M	-69.57M	-139.97M	12.9M	95.36M
Pretax Margin %	-	-	-10.6%	-	-	-	-	0.25%	0.33%
Income Tax+	0	0	-20.14K	0	0	0	0	1.97M	6.2M
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	0.85%	0.94%
Net Income+	-1.15M	-7.92M	-10.89M	-19.09M	-32.17M	-69.57M	-139.97M	10.93M	89.16M
Net Margin %	-	-	-10.6%	-	-	-	-	0.22%	0.31%
Net Income Growth %	-	-5.89%	-0.37%	-0.75%	-0.69%	-1.16%	-1.01%	1.08%	7.16%
Net Income (Continuing)	-1.15M	-7.92M	-10.89M	-19.09M	-32.17M	-69.57M	-139.97M	10.93M	89.16M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.27	-1.48	-0.97	-1.20	-1.71	-3.13	-5.49	0.39	3.00
EPS Growth %	-	-4.48%	0.34%	-0.24%	-0.42%	-0.83%	-0.75%	1.07%	6.69%
EPS (Basic)	-0.27	-1.48	-0.97	-1.20	-1.71	-3.13	-5.49	0.40	3.12
Diluted Shares Outstanding	4.28M	5.36M	11.2M	15.9M	18.79M	22.2M	25.49M	27.75M	29.74M
Basic Shares Outstanding	4.28M	5.36M	11.2M	15.9M	18.79M	22.2M	25.49M	27.15M	28.59M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.17M	49.91M	112.65M	195.88M	275.06M	442.27M	383.78M	587.91M	742.04M
Cash & Short-Term Investments	1.92M	49.59M	111.76M	193.69M	271.26M	438.1M	379.17M	532.18M	597.52M
Cash Only	1.92M	49.59M	103.67M	187.51M	268.27M	341.25M	161.9M	358.33M	344.87M
Short-Term Investments	0	0	8.09M	6.17M	2.99M	96.85M	217.27M	173.85M	252.65M
Accounts Receivable	0	0	0	0	0	0	0	42.04M	104.75M
Days Sales Outstanding	-	-	-	-	-	-	-	302.66	131.6
Inventory	0	0	0	0	0	0	0	6.99M	26.51M
Days Inventory Outstanding	-	-	-	-	-	-	-	824.02	482.3
Other Current Assets	0	0	0	0	0	0	4.61M	6.71M	13.27M
Total Non-Current Assets+	13K	200K	3.47M	13.14M	35.79M	184.03M	174.67M	230.45M	313.79M
Property, Plant & Equipment	13K	200K	3.01M	11.18M	34.17M	119.58M	169.73M	168.23M	161.45M
Fixed Asset Turnover	-	-	0.34x	-	-	-	-	0.30x	1.80x
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	497K	0	64.37M	4.62M	61.95M	152.11M
Other Non-Current Assets	0	0	452K	1.46M	1.61M	74K	324K	263K	231K
Total Assets+	2.18M	50.11M	116.12M	209.02M	310.84M	626.29M	558.45M	818.36M	1.06B
Asset Turnover	-	-	0.01x	-	-	-	-	0.06x	0.28x
Asset Growth %	-	21.97%	1.32%	0.8%	0.49%	1.01%	-0.11%	0.47%	0.29%
Total Current Liabilities+	43K	640K	2.6M	3.33M	15.45M	25.74M	28.85M	33.09M	102M
Accounts Payable	42K	193K	888K	1.02M	2.1M	8.4M	3.98M	1.85M	4.99M
Days Payables Outstanding	7.67K	3.06K	2.3K	382.61	415.09	-	-	218.13	90.7
Short-Term Debt	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	437K	1.36M	12K	26K	87K	267K	16.75M	2.4M
Current Ratio	50.44x	77.99x	43.39x	58.88x	17.80x	17.18x	13.30x	17.76x	7.28x
Quick Ratio	50.44x	77.99x	43.39x	58.88x	17.80x	17.18x	13.30x	17.55x	7.02x
Cash Conversion Cycle	-	-	-	-	-	-	-	908.56	523.2
Total Non-Current Liabilities+	1.85M	0	294K	2.78M	3.31M	6.98M	7.37M	6.62M	7.46M
Long-Term Debt	1.84M	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	2.78M	3.31M	6.98M	7.37M	6.62M	6.04M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	7K	0	294K	0	0	0	0	0	1.42M
Total Liabilities	1.89M	640K	2.89M	6.11M	18.76M	32.72M	36.22M	39.71M	109.46M
Total Debt+	1.84M	0	0	3.26M	11.55M	8.02M	8.93M	8.09M	7.26M
Net Debt	-80K	-49.59M	-103.67M	-184.25M	-256.72M	-333.22M	-152.97M	-350.23M	-337.6M
Debt / Equity	6.38x	-	-	0.02x	0.04x	0.01x	0.02x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	0.10x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-4.66x
Interest Coverage	-163.29x	-1.52x	-11.60x	-	-	-45.76x	-	-	-
Total Equity+	289K	49.47M	113.23M	202.91M	292.08M	593.58M	522.23M	778.64M	946.38M
Equity Growth %	-	170.19%	1.29%	0.79%	0.44%	1.03%	-0.12%	0.49%	0.22%
Book Value per Share	0.07	9.23	10.11	12.76	15.55	26.74	20.49	28.06	31.82
Total Shareholders' Equity	289K	49.47M	113.23M	202.91M	292.08M	593.58M	522.23M	778.64M	946.38M
Common Stock	0	0	0	0	0	0	0	0	0
Retained Earnings	-1.15M	-9.07M	-19.96M	-39.05M	-71.21M	-140.78M	-280.76M	-269.83M	-180.67M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-2K	-25K	2K	10K	6K	-163K	-728K	638K	-190K
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.31M	-3.89M	-9.45M	-18.71M	-26.08M	-47.94M	-100.57M	-88.8M	123.42M
Operating CF Margin %	-	-	-9.2%	-	-	-	-	-1.75%	0.42%
Operating CF Growth %	-	-1.97%	-1.43%	-0.98%	-0.39%	-0.84%	-1.1%	0.12%	2.39%
Net Income	-1.15M	-7.92M	-10.89M	-19.09M	-32.17M	-69.57M	-139.97M	10.93M	89.16M
Depreciation & Amortization	2K	23K	141K	748K	1.85M	2.77M	4.05M	5.01M	6.71M
Stock-Based Compensation	33K	246K	792K	1.24M	3.27M	15.32M	33.23M	39.93M	49.13M
Deferred Taxes	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	7K	3.26M	962K	67K	33K	1.49M	-690K	-106.79M	-7.12M
Working Capital Changes	-203K	498K	511K	-1.68M	928K	2.05M	2.81M	-37.88M	-14.46M
Change in Receivables	0	0	0	0	0	0	0	-42.04M	-62.71M
Change in Inventory	0	0	0	0	0	0	0	-4.47M	-11.91M
Change in Payables	42K	133K	112K	-199K	783K	712K	-1.25M	-101K	1.01M
Cash from Investing+	-15K	-210K	-10.32M	-4.97M	-11.18M	-226.77M	-114.08M	82.64M	-163.44M
Capital Expenditures	-15K	-210K	-2.23M	-6.4M	-14.84M	-68.34M	-52.98M	-11.8M	-4.24M
CapEx % of Revenue	-	-	2.18%	-	-	-	-	0.23%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0	100M	0
Cash from Financing+	3.25M	51.77M	73.85M	107.53M	118.02M	347.69M	35.35M	202.75M	27.01M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	-7.96M	-649K	-749K	-5.39M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.33M	-4.1M	-11.68M	-25.11M	-40.93M	-116.27M	-153.55M	-100.6M	119.18M
FCF Margin %	-	-	-11.37%	-	-	-	-	-1.98%	0.41%
FCF Growth %	-	-2.09%	-1.85%	-1.15%	-0.63%	-1.84%	-0.32%	0.34%	2.18%
FCF per Share	-0.31	-0.76	-1.04	-1.58	-2.18	-5.24	-6.02	-3.63	4.01
FCF Conversion (FCF/Net Income)	1.14x	0.49x	0.87x	0.98x	0.81x	0.69x	0.72x	-8.12x	1.38x
Interest Paid	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	5.67M

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-397.92%	-31.83%	-13.39%	-12.08%	-13%	-15.71%	-25.09%	1.68%	10.34%
Return on Invested Capital (ROIC)	-	-7780.43%	-189.36%	-117.38%	-91.62%	-34.63%	-34.59%	-20.63%	9.5%
Gross Margin	-	-	86.27%	-	-	-	-	93.9%	93.09%
Net Margin	-	-	-1060.27%	-	-	-	-	21.56%	30.69%
Debt / Equity	6.38x	-	-	0.02x	0.04x	0.01x	0.02x	0.01x	0.01x
Interest Coverage	-163.29x	-1.52x	-11.60x	-	-	-45.76x	-	-	-
FCF Conversion	1.14x	0.49x	0.87x	0.98x	0.81x	0.69x	0.72x	-8.12x	1.38x
Revenue Growth	-	-	-	-100%	-	-	-	-	473.02%

Frequently Asked Questions

Valuation & Price

Krystal Biotech, Inc. (KRYS) has a price-to-earnings (P/E) ratio of 94.0x. This suggests investors expect higher future growth.

Growth & Financials

Krystal Biotech, Inc. (KRYS) reported $373.2M in revenue for fiscal year 2024.

Krystal Biotech, Inc. (KRYS) grew revenue by 473.0% over the past year. This is strong growth.

Yes, Krystal Biotech, Inc. (KRYS) is profitable, generating $198.9M in net income for fiscal year 2024 (30.7% net margin).

Dividend & Returns

Krystal Biotech, Inc. (KRYS) has a return on equity (ROE) of 10.3%. This is reasonable for most industries.

Krystal Biotech, Inc. (KRYS) generated $165.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.